ProBioGen gains GMP authorisation for viral vectors and vaccines

ProBioGen has received extended GMP manufacturing authorisation for its Berlin facility, allowing it to manufacture viral vectors, vaccines and advanced therapy medicinal products (ATMPs) for clinical supply.

The authorisation and updated Good Manufacturing Practice (GMP) certificate were granted by the Berlin State Office for Health and Social Affairs (Lageso). They extend ProBioGen’s existing GMP manufacturing capabilities for therapeutic proteins to include viral drug substances and investigational medicinal products.

The dedicated viral manufacturing facility has drug substance production capacity of up to 200 litres, alongside in-house aseptic filling and quality control laboratories. The integrated setup is designed to support manufacturing from process development through to filled vials for clinical studies.

Aseptic manufacturing for viral products

The facility was qualified in accordance with EU GMP Annex 1 requirements for sterile medicinal products, including three successful aseptic process simulations.

Drug product filling uses an L1 system incorporating restricted access barrier system (RABS) technology. Its contamination-control procedures also include pre-use post-sterilisation integrity testing (PUPSIT) for filters used in the preparation of sterile media and buffers.

These capabilities are particularly relevant to viral products, for which sterilising filtration is not always suitable.

The expanded authorisation allows ProBioGen to bring together process development, GMP drug substance manufacturing and aseptic drug product filling within one facility, reducing the need for transfers between manufacturing partners.

Dr Simon Bulling, chief operating officer at ProBioGen, said: “This milestone builds on ProBioGen’s proven track record of more than two decades in GMP manufacturing of protein-based biopharmaceuticals, now combined with our deep expertise in viral vector technologies.”

He added: “With the authorization of our dedicated viral facility, we can offer an integrated service covering process development, GMP drug substance manufacturing and aseptic drug product filling for clinical supply.”

Bundibugyo ebolavirus vaccine programme

The facility will manufacture GMP drug substance for a Minapharm-led programme advancing a Bundibugyo ebolavirus vaccine candidate towards clinical evaluation.

The candidate is based on ProBioGen’s proprietary MVA-CR19 platform. The programme combines ProBioGen’s vaccine development and drug substance manufacturing capabilities with Minapharm’s commercial drug product manufacturing operations in Egypt.

The collaboration is relevant to efforts to develop vaccines against Bundibugyo ebolavirus, a cause of Ebola virus disease for which there are limited treatment and prevention options.

In August 2026, the Coalition for Epidemic Preparedness Innovations (CEPI) announced backing for the Minapharm-led vaccine programme, which aims to advance the candidate towards clinical trials.

Expansion of Berlin manufacturing capabilities

The authorisation also provides a foundation for ProBioGen’s planned activities at the Berlin Center for Gene and Cell Therapies (BC GCT), a biotechnology hub currently under construction.

ProBioGen will operate the future GMP facility at the centre, which is intended to expand manufacturing capabilities for biological medicines, viral vectors and advanced therapies.

The company, which has operated for more than 30 years, currently runs three manufacturing lines in Berlin and employs approximately 300 people.

The extended authorisation marks a further expansion of its manufacturing scope, positioning the company to support the development and clinical supply of viral vector-based therapies and vaccines.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox